|
2000 Journal Article Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patientsMak, KH, Effron, MB and Moliterno, DJ (2000). Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs & Aging, 16 (3), 179-187. doi: 10.2165/00002512-200016030-00003 |
|
1999 Journal Article Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot studyMakkar, R, Goff, B, Eigler, N, Sebastian, M, Fischell, T, Barr, L, D'Haem, C, Shah, PK, Effron, MB and Litvack, F (1999). Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. Catheterization and Cardiovascular Interventions, 48 (4), 430-434. doi: 10.1002/(SICI)1522-726X(199912)48:43.0.CO;2-G |
|
1999 Conference Publication Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary interventionMarks, DS, Effron, MB, Mensah, GA, Fitzpatrick, SE, Tcheng, JE and Kereiakes, DF (1999). Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
1999 Journal Article Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplastyBrener, SJ, Barr, LA, Burchenal, JEB, Wolski, KE, Effron, MB and Topol, EJ (1999). Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. American Journal of Cardiology, 84 (6), 728-+. doi: 10.1016/S0002-9149(99)00421-X |
|
1999 Journal Article Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)Ellis, SG, Effron, MB, Gold, HK, Leon, MB, Popma, JJ, Serruys, PWJC, Colombo, A, Cohen, N, Juran, N, Werner, W, Heuser, RR, Spooner, S, Rihal, CS, Fox, R, Leon, MB, Brennan, J, Ricci, D, Fox, R, Teirstein, PS, Norman, S, Morris, N, Zidar, J and Rund, M (1999). Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation, 100 (8), 799-806. |
|
1999 Journal Article Readministration of abciximab: Interim report of the ReoPro Readministration RegistryTcheng, JE, Kereiakes, DJ, Braden, GA, Jordan, RE, Mascelli, MA, Langrall, MA and Effron, MB (1999). Readministration of abciximab: Interim report of the ReoPro Readministration Registry. American Heart Journal, 138 (1), S33-S38. doi: 10.1053/hj.1999.v138.99236 |
|
1999 Journal Article Rapport? ReplyBrener, SJ, Topol, EJ, Moliterno, DJ, Barr, LA, Burchenal, JEB, Katz, S, George, BS, Jones, AA, Cohen, ED, Gainey, PC, White, HJ, Cheek, HB, Moses, JW and Effron, MB (1999). Rapport? Reply. Circulation, 99 (25), 3324-3324. |
|
1998 Journal Article Abciximab and alveolar hemorrhage - replyCohen, SA and Effron, MB (1998). Abciximab and alveolar hemorrhage - reply. New England Journal of Medicine, 339 (25), 1862-1863. |
|
1998 Conference Publication Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3)Tcheng, JE, Kereiakes, DJ, Braden, GA, Lincoff, AM, Mascelli, MA, Langrall, MA, Damaraju, LV, Schantz, AR, Barnathan, ES and Effron, MB (1998). Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
1998 Conference Publication Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trialBrener, SJ, Barr, LA, Burcehnal, JEB, Katz, S and Effron, MB (1998). Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trial. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
1998 Conference Publication Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trialBrener, SJ, Cannata, RK, Effron, MB and Topol, NJ (1998). Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trial. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
1998 Conference Publication Abciximab accelerates the reperfusion process after primary angioplasty for acute myocardial infarction, without affecting enzymatic infarct sizeBrener, SJ, Cannata, RK and Effron, MB (1998). Abciximab accelerates the reperfusion process after primary angioplasty for acute myocardial infarction, without affecting enzymatic infarct size. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
1998 Conference Publication The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot studyMakkar, R, Goff, B, Eigler, N, Fischell, T, Barr, L, D'Haem, C, Shah, PK, Effron, MB and Litvack, F (1998). The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. NEW YORK: EXCERPTA MEDICA INC. |
|
1998 Journal Article Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarctionBrener, SJ, Barr, LA, Burchenal, JEB, Katz, S, George, BS, Jones, AA, Cohen, ED, Gainey, PC, White, HJ, Cheek, HB, Moses, JW, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation, 98 (8), 734-741. doi: 10.1161/01.CIR.98.8.734 |
|
1998 Conference Publication Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trialBrener, SJ, Barr, LA, Cohen, ED, White, HJ, Moliterno, DJ, Cheek, HB, Effron, MB and Topol, EJ (1998). Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83942-3 |
|
1998 Conference Publication Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3)Tcheng, JE, Kereiakes, DJ, George, BS, Braden, G, Langrall, MA, Zelinger, D, Jordan, R and Effron, MB (1998). Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3). NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83944-7 |
|
1998 Conference Publication Synergy of abciximab and ticlopidine in patients undergoing intracoronary stentingKleiman, NS, Graziadei, N, Lance, E, Maresh, K, Taylor, J, Higginbotham, J, Edwards, A, Effron, MB, Mascelli, MA and Jordan, RE (1998). Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84740-7 |
|
1998 Conference Publication Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trialBarr, LA, Brener, SJ, Jones, AA, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84737-7 |
|
1998 Conference Publication Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORTBrener, SJ, Ellis, SG, Burchenal, JEB, Katz, S, Effron, MB and Topol, EJ (1998). Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84709-2 |
|
1997 Conference Publication Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER resultsEllis, SG, Serruys, PW, Popma, JJ, Teirstein, PS, Ricci, DR, Gold, HK and Effron, MB (1997). Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. DALLAS: AMER HEART ASSOC. |
